Merus (MRUS) Presents At J.P. Morgan Healthcare Conference

• HNSCC (interim data presented at ENA) • Gastric/Esophageal (not yet presented) • Data cutoff date: 09-Aug-2021 • Enrollment: 10 patients, 7 evaluable for efficacy • Three patients recently enrolled excluded from interim analysis (first dose <8 weeks from data cutoff date) | --- | --- | --- | |-------|---------------------------------------|-------------------| | | | | | | HNSCC Patient Characteristics (N=10) | | | | Age (years), median (range) | 65 (50-77) | | | Male / female | 9 (90%) / 1 (10%) | | | ECO ...